SEPT9 and PAI-1 are immunohistochemical biomarkers of the hepatocellular carcinoma immune microenvironment
SEPT9 is associated with PAI-1, a pro-tumorigenic protein. Both SEPT9 and PAI-1 are linked to advanced HCC grades. SEPT9 and PAI-1 positive HCCs have distinct CXCR2+ immune cell landscapes. Further investigation is needed to elucidate a possible SEPT9/PAI-1 interaction and the clinical utility of SEPT9 IHC in HCC.
Authors
- Hwajeong Lee (ORCID: https://orcid.org/0000-0001-7005-6278)
- Eundong Park (ORCID: https://orcid.org/0000-0002-7467-2825)
- Anne Chen (ORCID: https://orcid.org/0000-0002-2945-8424)
- Paul J. Higgins (ORCID: https://orcid.org/0000-0001-5208-1197)
- Michel Kmeid (ORCID: https://orcid.org/0000-0001-8546-5744)
- Xin Wang (ORCID: https://orcid.org/0000-0001-8051-1481)
- Nusret Bekir Subasi
Institutions
- Cleveland Clinic (US)
- Washington University in St. Louis (US)
- Albany Medical Center Hospital (US)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1007/s12672-025-02252-5
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00